title: Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium.
abstract: Heparin-induced thrombocytopenia (HIT) is frequently associated with antibodies (Abs) to heparin-PF4 complexes (H-PF4). In order to investigate whether there are variations in specificity of Abs, we studied 63 samples from patients with suspected HIT. Two groups of samples were separated after comparing their reactivity against H-PF4 or recombinant PF4 (r-PF4) using ELISA. In group Ab1 (n = 46), Abs only or mainly bound to H-PF4 complexes and thus most of the epitopes recognized probably involved both heparin and PF4. In group Ab2 (n = 17), Abs exhibited similar reactivity to r-PF4 and H-PF4, and the antigens recognized were possibly neoepitopes mainly expressed by modified PF4 and by H-PF4 complexes. Platelet activation tests were positive with 56 samples containing high titres of Abs to H-PF4. Most samples (n = 59) contained IgG antibodies, often associated with IgA antibodies which were more frequently found in group Ab2, and/or IgM. With unfractionated heparin treatment, HIT was associated with Ab1 or Ab2 antibodies, whereas only Ab1 antibodies were detected after low-molecular-weight heparin (LMWH). Furthermore, cross-reactivity with danaparoid sodium was present only in group Ab1 and mainly involved LMWH-treated patients.
authors.affiliation: Laboratoire d'Hématologie-Hémostase, Hôpital Trousseau, Tours, France.
authors.forename: C
authors.initials: C
authors.lastname: Pouplard
authors.forename: J
authors.initials: J
authors.lastname: Amiral
authors.forename: J Y
authors.initials: JY
authors.lastname: Borg
authors.forename: A M
authors.initials: AM
authors.lastname: Vissac
authors.forename: B
authors.initials: B
authors.lastname: Delahousse
authors.forename: Y
authors.initials: Y
authors.lastname: Gruel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000276:immunology*; D000918:Antibody Specificity; D002809:Chondroitin Sulfates / Q000276:immunology*; D003871:Dermatan Sulfate / Q000276:immunology*; D004338:Drug Combinations; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006493:Heparin / Q000009:adverse effects / Q000276:immunology*; D006497:Heparan Sulfate / Q000276:immunology*; D006801:Humans; D016209:Interleukin-8 / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000276:immunology; D015539:Platelet Activation; D010978:Platelet Factor 4 / Q000276:immunology; D013921:Thrombocytopenia / Q000139:chemically induced / Q000276:immunology*; D001620:beta-Thromboglobulin
chemical_list: D000906:Antibodies; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006493:Heparin; D006497:Heparan Sulfate; D016209:Interleukin-8; D010455:Peptides; D010978:Platelet Factor 4; D001620:beta-Thromboglobulin; C061615:PPBP protein, human; C009862:connective tissue-activating peptide; C035838:danaparoid